Journal of Virus Eradication (Sep 2023)

The central nervous system is a potential reservoir and possible origin of drug resistance in hepatitis B infection

  • Lijun Xu,
  • Minghan Zhou,
  • Xiuming Peng,
  • Yufan Xu,
  • Fan Huang,
  • Linyun Wang,
  • Xiaorong Peng,
  • Zongxing Yang,
  • Ran Tao,
  • Guanjing Lang,
  • Qing Cao,
  • Minwei Li,
  • Ying Huang,
  • Biao Zhu,
  • Yan Xu

Journal volume & issue
Vol. 9, no. 3
p. 100348

Abstract

Read online

Background: The significance of hepatitis B virus (HBV) in cerebrospinal fluid (CSF) is unclear. Methods: Synchronous serum and CSF samples were collected from 13 patients. HBV DNA, full-length genome, quasispecies, phylogenetic tree, compartmentalization and mutation of the reverse transcriptase (RT) region were performed based on PCR and sequencing methods. Results: HBV DNA was detected in the CSF of 3 antiviral-naïve individuals and 1 individual after successful antiviral therapy. Complete full-length HBV genomes were isolated from the CSF of 5 individuals, including 2 with undetectable serum HBV DNA. Ten individuals exhibited distinct CSF-serum quasispecies, 8 harbored independent CSF-serum genetic compartmentalization and phylogenetic trees, and 5 lamivudine/entecavir-associated resistance mutations only in the CSF. The frequencies of rtL180M and rtM204I/V mutations in both serum and CSF were higher in HIV-HBV-coinfected individuals than in the HBV-monoinfected ones (serum: rtL180M: 3.9% vs. 0, P = 0.004; rtM204I/V: 21.3% vs. 0, P < 0.001; CSF: rtL180M: 7.6% vs. 0, P = 0.026; rtM204I/V 7.6% vs. 1.6%, P = 0.097). Conclusion: CSF is a potential HBV reservoir, and HBV in CSF harbors distinct evolution and mutation characteristics from those in serum. HIV infection increases the possibility of HBV rtL180M and rtM204I/V mutations in both serum and CSF.

Keywords